New therapies for autoimmune myasthenia gravis.

Lancet Neurol

Department of Neurology, Leiden University Medical Centre, Leiden 2333 ZA, Netherlands. Electronic address:

Published: May 2023

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(23)00125-4DOI Listing

Publication Analysis

Top Keywords

therapies autoimmune
4
autoimmune myasthenia
4
myasthenia gravis
4
therapies
1
myasthenia
1
gravis
1

Similar Publications

Introduction: Leucine-rich glioma-inactivated 1 (LGI-1) antibody encephalitis is a rare subtype of autoimmune limb encephalitis (ALE), which is marked by rapid neuropsychiatric decline. This report details a comprehensive approach to its diagnosis and management.

Assessment: In this case, a 68-year-old man presented with aggressive behaviors, cognitive decline, and seizure-like episodes.

View Article and Find Full Text PDF

While the gluten-free diet (GFD) is primarily used to treat celiac disease (CD), recent research suggests it may also offer benefits for autoimmune-related diseases (ARDs), though findings remain inconsistent. This study aimed to investigate the potential protective effect of a GFD against ARDs by Mendelian Randomization (MR) analysis. Utilizing data from over 500,000 samples from the UK Biobank and other publicly available genome-wide association studies (GWAS), MR analysis revealed a significant negative causal relationship between GFD and the risk of developing rheumatoid arthritis (RA) (OR = 0.

View Article and Find Full Text PDF

Acute kidney injury following CAR-T cell therapy: a nephrologist's perspective.

Clin Kidney J

January 2025

Department of Medicine, Universidad Autonoma de Madrid and IIS-Fundacion Jimenez Diaz, Madrid, Spain.

Chimeric antigen receptor T (CAR-T) cell therapy, an emerging personalized immunotherapy for various haematologic malignancies, autoimmune diseases and other conditions, involves the modification of patients' T cells to express a chimeric antigen receptor that recognizes tumour or autoimmune cell antigens, allowing CAR-T cells to destroy cancerous and other target cells selectively. Despite remarkable clinical improvements in patients, multiple adverse effects have been associated with CAR-T cell therapy. Among the most recognized adverse effects are cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and tumour lysis syndrome.

View Article and Find Full Text PDF

Background: Thymoma is a rare mediastinal neoplasm originating from thymic epithelial cells, often associated with paraneoplastic syndromes. These syndromes can manifest as a range of autoimmune disorders, including myasthenia gravis, pure red cell aplasia, and aplastic anemia. Clinical trials involving the use of immune checkpoint inhibitors (ICIs) in thymoma have been complicated by a high incidence of immune-related adverse effects (irAEs).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!